迈向全民健康覆盖的进程如何可能助长劣质药物：伊丽莎白·皮萨尼的一篇文章
How moves towards universal health coverage could encourage poor quality drugs: an essay by Elizabeth Pisani.
作者信息
Pisani Elizabeth
机构信息
Erasmus School of Health Policy and Management, Rotterdam, The Netherlands, and King's College London, UK.
出版信息
BMJ. 2019 Sep 4;366:l5327. doi: 10.1136/bmj.l5327.
Abstract
Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs, warns
摘要
全民健康覆盖依赖于价格可承受的药品。但世界卫生组织警告称，在不投资于质量保证的情况下压低价格，将会增加不合格药品和假药的销量。
相似文献
1
How moves towards universal health coverage could encourage poor quality drugs: an essay by Elizabeth Pisani.迈向全民健康覆盖的进程如何可能助长劣质药物：伊丽莎白·皮萨尼的一篇文章
BMJ. 2019 Sep 4;366:l5327. doi: 10.1136/bmj.l5327.
2
Elizabeth Pisani.伊丽莎白·皮萨尼
Lancet. 2008 May 3;371(9623):1497. doi: 10.1016/S0140-6736(08)60643-1.
3
Modelling the implications of moving towards universal coverage in Tanzania.在坦桑尼亚实现全民覆盖的影响建模。
Health Policy Plan. 2012 Mar;27 Suppl 1:i88-100. doi: 10.1093/heapol/czs009.
4
Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): towards consensus and improved guidance.为注射吸毒者普及艾滋病毒预防、治疗和护理设定目标：达成共识并完善指导意见。
Int J Drug Policy. 2008 Apr;19 Suppl 1:S5-14. doi: 10.1016/j.drugpo.2007.12.002. Epub 2008 Feb 12.
5
Health insurance expansion through states in a pluralistic system.在多元化体系中，通过各州扩大医疗保险覆盖范围。
J Health Polit Policy Law. 2001 Jun;26(3):581-615. doi: 10.1215/03616878-26-3-581.
6
An analysis of perceived access to health care in Europe: How universal is universal coverage?欧洲医疗保健可及性认知分析：全民覆盖有多普及？
Health Policy. 2015 Sep;119(9):1133-44. doi: 10.1016/j.healthpol.2015.07.004. Epub 2015 Jul 19.
7
Health-financing reforms in southeast Asia: challenges in achieving universal coverage.东南亚的卫生筹资改革：实现全民覆盖的挑战。
Lancet. 2011 Mar 5;377(9768):863-73. doi: 10.1016/S0140-6736(10)61890-9. Epub 2011 Jan 25.
8
Using stakeholder analysis to support moves towards universal coverage: lessons from the SHIELD project.利用利益相关者分析支持全民覆盖的举措：SHIELD 项目的经验教训。
Health Policy Plan. 2012 Mar;27 Suppl 1:i64-76. doi: 10.1093/heapol/czs007.
9
Moving towards universal health insurance in China: performance, issues and lessons from Thailand.迈向全民健康保险的中国：泰国的绩效、问题和经验教训。
Soc Sci Med. 2011 Aug;73(3):359-66. doi: 10.1016/j.socscimed.2011.06.002. Epub 2011 Jun 21.
10
[Effective access to health services: operationalizing universal health coverage].[有效获得卫生服务：实现全民健康覆盖的操作化]
Salud Publica Mex. 2015 Mar-Apr;57(2):180-6.
引用本文的文献
1
Understanding the regulatory-procurement interface for medicines in Africa via publicly available information on standards, implementation, and enforcement in five countries.通过五个国家关于标准、实施和执行的公开信息来了解非洲药品监管与采购之间的关系。
J Pharm Policy Pract. 2025 Jan 9;18(1):2436898. doi: 10.1080/20523211.2024.2436898. eCollection 2025.
2
Relationship between Prices and Quality of Essential Medicines from Different Manufacturers Collected in Cameroon, the Democratic Republic of the Congo, and Nigeria.喀麦隆、刚果民主共和国和尼日利亚收集的不同制造商生产的基本药物价格与质量之间的关系。
Am J Trop Med Hyg. 2024 Oct 8;111(6):1378-1395. doi: 10.4269/ajtmh.24-0309. Print 2024 Dec 4.
3
Variation in Price of Cardiovascular and Diabetes Medicine in Indonesia, and Relationship with Quality: A Mixed Methods Study in East Java.印度尼西亚心血管和糖尿病药物价格的变化及其与质量的关系：东爪哇的一项混合方法研究。
Am J Trop Med Hyg. 2023 May 9;108(6):1287-1299. doi: 10.4269/ajtmh.22-0692. Print 2023 Jun 7.
4
A study of the quality of cardiovascular and diabetes medicines in Malang District, Indonesia, using exposure-based sampling.印度尼西亚玛琅地区心血管和糖尿病药物质量的基于暴露采样的研究。
BMJ Glob Health. 2022 Nov;7(11). doi: 10.1136/bmjgh-2022-009762.
5
"": pharmaceutical governance and on-the-ground ethical labour in Ghana.《加纳的药品治理与实地道德劳动》 （原文冒号前为空，推测这是某个文献或项目的标题之类，这里根据意思补充完整翻译）
Glob Bioeth. 2022 Jul 26;33(1):103-121. doi: 10.1080/11287462.2022.2103899. eCollection 2022.
6
Elusive quality: the challenges and ethical dilemmas faced by international non-governmental organisations in sourcing quality assured medical products.难以捉摸的质量：国际非政府组织在采购质量保证的医疗产品时面临的挑战和道德困境。
BMJ Glob Health. 2021 May;6(Suppl 3). doi: 10.1136/bmjgh-2020-004339.
7
Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.在追求全民健康覆盖的同时维持药品质量面临的挑战：来自印度尼西亚的定性分析
BMJ Glob Health. 2021 May;6(Suppl 3). doi: 10.1136/bmjgh-2020-003663.
8
Strengthening multisectoral coordination on antimicrobial resistance: a landscape analysis of efforts in 11 countries.加强抗菌药物耐药性的多部门协调：对11个国家所做努力的全景分析
J Pharm Policy Pract. 2021 Feb 28;14(1):27. doi: 10.1186/s40545-021-00309-8.
9
Tackling the blind spot of poor-quality medicines in Universal Health Coverage.解决全民健康覆盖中劣质药品的盲点问题。
J Pharm Policy Pract. 2020 May 11;13:40. doi: 10.1186/s40545-020-00208-4. eCollection 2020.
10
Quality of medicines for life-threatening pregnancy complications in low- and middle-income countries: A systematic review.中低收入国家危及生命的妊娠并发症药物质量：系统评价。
PLoS One. 2020 Jul 10;15(7):e0236060. doi: 10.1371/journal.pone.0236060. eCollection 2020.
本文引用的文献
1
Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.识别不合格和假药的市场风险：基于中国、印度尼西亚、土耳其和罗马尼亚定性研究的分析框架。
Wellcome Open Res. 2019 Apr 16;4:70. doi: 10.12688/wellcomeopenres.15236.1. eCollection 2019.
2
Estimated costs of production and potential prices for the WHO Essential Medicines List.世界卫生组织基本药物清单的估计生产成本及潜在价格。
BMJ Glob Health. 2018 Jan 29;3(1):e000571. doi: 10.1136/bmjgh-2017-000571. eCollection 2018.
3
Essential medicines for universal health coverage.全民健康覆盖的基本药物。
Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8.
Zotero 插件